To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03610971
Title Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
Emory -Winship Cancer Institute Atlanta Georgia 30322 United States Details
Memorial Sloan Kettering - Bergen Montvale New Jersey 07645 United States Details
Roswell Park Comprehensive Cancer Center Buffalo New York 14263 United States Details
David H. Koch Center for Cancer Care at Memorial Sloan Kettering New York New York 10021 United States Details
Duke University Hospital Durham North Carolina 27710 United States Details
Oregon Health & Science University Portland Oregon 97239 United States Details
Froedtert Hospital & the Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field